Outcomes Among Acute Heart Failure Emergency Department Patients by Preserved vs. Reduced Ejection Fraction
Dana R. Sax(Kaiser Permanente), Dustin G. Mark(Kaiser Permanente), Jie Huang(Kaiser Permanente), Alan B. Storrow(Vanderbilt University Medical Center), Sean P. Collins(Wayne State University), Jamal S. Rana(Kaiser Permanente), Mary E. Reed(Kaiser Permanente), Dandan Liu(Vanderbilt University Medical Center)
Cited by 12
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2020|489
Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2017|406
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
|European Heart Journal|2022|213
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study
|European Heart Journal|2009|188